OncoGenex outlines plans for $48 million IPO

Canada's OncoGenex Technologies plans to raise up to $48 million in an IPO. The biotech has three products in development to inhibit the production of proteins linked to the resistance of treatments. The drug developer was founded in 2000 and has raised $35 million in venture capital. RBC Capital Markets will be the sole lead manager for the offering, and Needham & Company, Lazard Capital Markets, Canaccord Adams, and Susquehanna Financial Group are the co-managers.

- see this press release on the IPO
- here's the report from TechFinance.ca